medigraphic.com
Asociación Mexicana de Gastroenterología

2005, Number 4

<< Back Next >>

Rev Gastroenterol Mex 2005; 70 (4)

Prevalence of antibodies against hepatitis C and B viruses in patients with systemic lupus erythematosus

Mercado U, Avendaño-Reyes M, Araiza-Casillas R, Díaz-Molina R

Language: Spanish
References: 13
Page: 399-401
PDF size: 31.96 Kb.


ABSTRACT

Viruses might be one of the environmental agents that trigger systemic lupus erythematosus (SLE). Objective: To determine the prevalence of hepatitis C virus (HCV) and hepatitis B virus (HBV) antibodies in patients with SLE. Methods: We investigated 110 SLE patients (106 women and 4 men, mean age 35.1 years) who fulfilled the criteria for SLE of the American College of Rheumatology. Three hundred blood donors served as controls. Antibodies against HCV and HBV were tested by a third generation ELISA. Positive results for anti-HCV were further studied by a third generation recombinant immunoblot assay (RIBA 3.0) and polymerase chain reaction (PCR). A positive ELISA assay was considered when the result was positive on two consecutive determinations. Results: Antibodies to HCV were present in 3 blood donors (1%), compared with 2 SLE patients (p = 0.4, Fisher’s test). One SLE patient was RIBA positive and was lost for follow-up, and the another was confirmed by PCR. This patient had chronic hepatitis and a history of blood transfusion. No patient or control was HBV positive. Conclusions: The prevalence of antibodies against HCV and HBV was not higher than in blood donors and the relation between these viruses and SLE could not be established.


REFERENCES

  1. Wener MH, Johnson RJ, Sasso RH, et al. Hepatitis C virus and rheumatic disease. J Rheumatol 1996; 23: 953-59.

  2. Martin P. Hepatitis C: more than just a liver disease. Gastroenterology 1993; 104: 320-3.

  3. Inman RD. Rheumatic manifestations of hepatitis B virus infection. Sem Arthritis Rheum 1928; 11: 406-20.

  4. Buskila D, Sikuler E, Shoenfeld Y. Hepatitis C virus. Autoimmunity and rheumatic diseases. Lupus 1997; 6: 685-89.

  5. Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997; 127: 423-8.

  6. Mercado U, Avendaño-Reyes M. Development of myositis after hepatitis C virus infection. Clin Exp Rheumatol, en prensa.

  7. Tan Em, et al. Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 2002; 46: 1139-54.

  8. McMurray RW, Elbourne K. Hepatitis C virus infection and autoimmunity. Sem Arthritis Rheum 1997; 26: 689-701.

  9. Karakoc Y, Dilek K, Gullullu M, et al. Prevalence of hepatitis C virus antibody in patients with systemic lupus erythematosus. Ann Rheum Dis 1997; 56: 570-1.

  10. Kowdley KV, Subler DE, Scheffel J, et al. Hepatitis C virus antibodies in systemic lupus erythematosus. J Clinc Gastroenterol 1997; 25: 437-9.

  11. Abu Shakra M, El-Sana S, Margalith M, et al. Hepatitis B and C viruses serology in patients with SLE. Lupus 1997; 6: 543-4.

  12. Ramos-Casals M, Font J, Garcia-Carrasco M, et al. Hepatitis C virus infection mimicking systemic lupus erythematosus. Arthritis Rheum 2000; 43: 2801-6.

  13. Mendez-Sanchez N, Baptista-Gonzalez H, Sanchez-Gomez RH y cols. Prevalencia de hepatitis B y C en donadores de sangre en un hospital de tercer nivel de la Ciudad de México. Sal Pub Mex 1999; 41: 475-8.




2020     |     www.medigraphic.com